Remogliflozin etabonate

Remogliflozin etabonate (INN/USAN) is a proposed drug for the treatment of type 2 diabetes being investigated by GlaxoSmithKline. It did not undergo further development after phase II.

Method of action
Remogliflozin inhibits the sodium-glucose transport proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.